Roy H. Campbell

Roy H. Campbell

Auto-generated profile, based on publicly available information

Roy H. Campbell

Department of Computer Science, University of Illinois at Urbana-Champaign

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
MMMary B. Makarious
Mary B. Makarious
HLHampton L. Leonard
Hampton L. Leonard
DVDan Vitale
Dan Vitale
HIHirotaka Iwaki
Hirotaka Iwaki
LSLana Sargent
Lana Sargent
MNMike A. Nalls
Mike A. Nalls
Personalized medicine promises individualized disease prediction and treatment. The convergence of machine learning (ML) and available multimodal data is key moving forward. We build upon previous work to deliver multimodal predictions of Parkinson’s disease (PD) risk and systematically develop a model using GenoML, an automated ML package, to make improved multi-omic predictions of PD, validated in an external cohort. We investigated top features, constructed hypothesis-free disease-relevant networks, and investigated drug–gene interactions. We performed automated ML on multimodal data from the Parkinson’s progression marker initiative (PPMI). After selecting the best performing algorithm, all PPMI data was used to tune the selected model. The model was validated in the Parkinson’s Disease Biomarker Program (PDBP) dataset. Our initial model showed an area under the curve (AUC) of 89.72% for the diagnosis of PD. The tuned model was then tested for validation on external data (PDBP, AUC 85.03%). Optimizing thresholds for classification increased the diagnosis prediction accuracy and other metrics. Finally, networks were built to identify gene communities specific to PD. Combining data modalities outperforms the single biomarker paradigm. UPSIT and PRS contributed most to the predictive power of the model, but the accuracy of these are supplemented by many smaller effect transcripts and risk SNPs. Our model is best suited to identifying large groups of individuals to monitor within a health registry or biobank to prioritize for further testing. This approach allows complex predictive models to be reproducible and accessible to the community, with the package, code, and results publicly available.

16 December 2022 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
ADAnant Dadu
Anant Dadu
VSVipul Satone
Vipul Satone
Rachneet KaurRachneet Kaur
Rachneet Kaur
SHSayed Hadi Hashemi
Sayed Hadi Hashemi
HLHampton Leonard
Hampton Leonard
FFFaraz Faghri
Faraz Faghri
The clinical manifestations of Parkinson’s disease (PD) are characterized by heterogeneity in age at onset, disease duration, rate of progression, and the constellation of motor versus non-motor features. There is an unmet need for the characterization of distinct disease subtypes as well as improved, individualized predictions of the disease course. We used unsupervised and supervised machine learning methods on comprehensive, longitudinal clinical data from the Parkinson’s Disease Progression Marker Initiative (n = 294 cases) to identify patient subtypes and to predict disease progression. The resulting models were validated in an independent, clinically well-characterized cohort from the Parkinson’s Disease Biomarker Program (n = 263 cases). Our analysis distinguished three distinct disease subtypes with highly predictable progression rates, corresponding to slow, moderate, and fast disease progression. We achieved highly accurate projections of disease progression 5 years after initial diagnosis with an average area under the curve (AUC) of 0.92 (95% CI: 0.95 ± 0.01) for the slower progressing group (PDvec1), 0.87 ± 0.03 for moderate progressors, and 0.95 ± 0.02 for the fast-progressing group (PDvec3). We identified serum neurofilament light as a significant indicator of fast disease progression among other key biomarkers of interest. We replicated these findings in an independent cohort, released the analytical code, and developed models in an open science manner. Our data-driven study provides insights to deconstruct PD heterogeneity. This approach could have immediate implications for clinical trials by improving the detection of significant clinical outcomes. We anticipate that machine learning models will improve patient counseling, clinical trial design, and ultimately individualized patient care.

10 September 2011 in Cluster Computing
Verified
Journal Article
Closed access
PDF file
AVAbhishek Verma
Abhishek Verma
BCBrian Cho
Brian Cho
NZNicolas Zea
Nicolas Zea
IGIndranil Gupta
Indranil Gupta
RCRoy H. Campbell
Roy H. Campbell

1 September 2020 in Chaos, Solitons & Fractals
Verified
Journal Article
Closed access
SBSayantani Basu
Sayantani Basu
RCRoy H. Campbell
Roy H. Campbell

4 June 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
FFFaraz Faghri
Faraz Faghri
SHSayed Hadi Hashemi
Sayed Hadi Hashemi
HLHampton Leonard
Hampton Leonard
SSSonja Scholz
Sonja Scholz
RCRoy H. Campbell
Roy H. Campbell
ASAndrew B. Singleton
Andrew B. Singleton
Background: The clinical manifestations of Parkinson disease are characterized by heterogeneity in age at onset, disease duration, rate of progression, and constellation of motor versus nonmotor features. Due to these variable presentations, counseling of patients about their individual risks and prognosis is limited. There is an unmet need for predictive tests that facilitate early detection and characterization of distinct disease subtypes as well as improved, individualized predictions of the disease course. The emergence of machine learning to detect hidden patterns in complex, multi-dimensional datasets provides unparalleled opportunities to address this critical need. Methods and Findings: We used unsupervised and supervised machine learning approaches for subtype identification and prediction. We used machine learning methods on comprehensive, longitudinal clinical data from the Parkinson Disease Progression Marker Initiative (PPMI) (n=328 cases) to identify patient subtypes and to predict disease progression. The resulting models were validated in an independent, clinically well-characterized cohort from the Parkinson Disease Biomarker Program (PDBP) (n=112 cases). Our analysis distinguished three distinct disease subtypes with highly predictable progression rates, corresponding to slow, moderate and fast disease progressors. We achieved highly accurate projections of disease progression four years after initial diagnosis with an average Area Under the Curve of 0.93 (95% CI: 0.96 ± 0.01 for PDvec1, 0.87 ± 0.03 for PDvec2, and 0.96 ± 0.02 for PDvec3). We have demonstrated robust replication of these findings in the independent validation cohort. Conclusions: These data-driven results enable clinicians to deconstruct the heterogeneity within their patient cohorts. This knowledge could have immediate implications for clinical trials by improving the detection of significant clinical outcomes that might have been masked by cohort heterogeneity. We anticipate that machine learning models will improve patient counseling, clinical trial design, allocation of healthcare resources and ultimately individualized clinical care.

1 July 2010
Verified
Conference Paper
Open access
AVAbhishek Verma
Abhishek Verma
XLXavier Llora
Xavier Llora
SVShivaram Venkataraman
Shivaram Venkataraman
DGDavid E. Goldberg
David E. Goldberg
RCRoy H. Campbell
Roy H. Campbell
This paper shows how the extended compact genetic algorithm can be scaled using data-intensive computing techniques such as MapReduce. Two different frameworks (Hadoop and MongoDB) are used to deploy MapReduce implementations of the compact and extended compact genetic algorithms. Results show that both are good choices to deal with large-scale problems as they can scale with the number of commodity machines, as opposed to previous efforts with other techniques that either required specialized high-performance hardware or shared memory environments.